科濟藥業控股有限公司 CARSGEN THERAPEUTICS HOLDINGS LIMITED

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2023🗂️ Report periods on file: 2023, 2022

In its 2023 reporting, 科濟藥業控股有限公司 CARSGEN THERAPEUTICS HOLDINGS LIMITED disclosed greenhouse gas emissions of 15.3K tCO2e. By scope: Scope 1: 3.6K tCO2e; Scope 2: 11.7K tCO2e. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
15.3K tCO2e
2023
💧
Water Usage
90.0K tons
2023
♻️
Waste
152.33 tons
2023
⚙️
Energy Use
27.6K MWh
2023

📊 Emissions by Scope (2023)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).3.6K tCO2e
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.11.7K tCO2e

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
202315.3K tCO2e
202217.2K tCO2e

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🌱 ESG Focus Areas

Product quality and safetyPrivacy and information protectionProduct R&D and innovationHealth accessibility and clinical experiment safetyBusiness ethicsEmployee rights protectionOccupational health and safety

⚠️ Challenges & Risks +

  • FDA placed a clinical hold on zevor-cel, satricabtagene autoleucel and CT071 due to CMC observations related to the RTP Manufacturing Facility in Durham, North Carolina.
  • Significant net losses and net operating cash outflows since inception.
  • Need for additional capital to meet operating cash requirements.
  • Limited operating history.
  • Competition in the rapidly changing biopharmaceutical industry.
  • Lengthy and expensive clinical development process with uncertain outcome.
  • Extensive government regulation.
  • Complex manufacturing process for cell therapies.
  • Limited market opportunities for product candidates.
  • Limited marketing and sales organization.

📋 Report Information

Reporting Period: 2023
Frameworks: Appendix C2 Environmental, Social and Governance Reporting Guide to the Main Board Listing Rules of Stock Exchange of Hong Kong Limited